Saudi Arabia has announced a significant stride in its healthcare sector, with a landmark agreement signed during the Global Health Forum in Riyadh. The agreement signals the country’s commitment to establishing a local insulin production industry, fostering self-sufficiency and knowledge transfer within the pharmaceutical domain.
In collaboration with the Local Content and Government Procurement Authority and the Spending Efficiency and Government Projects Authority (Expro), the agreement emphasizes the activation of a contracting method aimed at localizing the insulin industry and facilitating the exchange of critical knowledge.
The agreement was finalized through the combined efforts of the National Company for the Unified Purchase of Medicines, Medical Devices, and Supplies (NUPCO), Sudair Pharmaceuticals Company, and Sanofi Company, highlighting a cohesive approach to bolstering the country’s healthcare capabilities.
Anticipated outcomes of this pact include the amplification of the government’s procurement capabilities and the achievement of self-sufficiency in various priority products and sectors, with a specific focus on localizing the production of select insulin products.
